A study presented at last month’s American College of Cardiology meeting indicates that an ultrasound contrast agent under development by Acusphere of Cambridge, MA, could be used in a continuous mode. Imaging continuously with AI-700 could
A study presented at last months American College of Cardiology meeting indicates that an ultrasound contrast agent under development by Acusphere of Cambridge, MA, could be used in a continuous mode. Imaging continuously with AI-700 could help clinicians overcome some of the shortcomings of other agents, which have short persistence times because their contrast-enhancing microbubbles break up under ultrasound beams. Acusphere believes that the AI-700 microbubbles may have longer persistence times because they are made from synthetic polymers. AI-700 is in phase I clinical trials.
Emerging Perspectives on PSMA PET Radiotracers: An Interview with Kenneth J. Pienta, MD
April 24th 2024In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.